CY1105059T1 - Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα - Google Patents

Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα

Info

Publication number
CY1105059T1
CY1105059T1 CY20061100872T CY061100872T CY1105059T1 CY 1105059 T1 CY1105059 T1 CY 1105059T1 CY 20061100872 T CY20061100872 T CY 20061100872T CY 061100872 T CY061100872 T CY 061100872T CY 1105059 T1 CY1105059 T1 CY 1105059T1
Authority
CY
Cyprus
Prior art keywords
viro
lymphotoxin
reversal
blocking
induced systemic
Prior art date
Application number
CY20061100872T
Other languages
English (en)
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Biogen Idec Ma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma, Inc. filed Critical Biogen Idec Ma, Inc.
Publication of CY1105059T1 publication Critical patent/CY1105059T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Η εφεύρεση παρέχει μεθόδους για την επαγωγή μίας αντιικής απάντησης σε ένα άτομο, που περιλαμβάνει την χορήγηση μίας αποτελεσματικής ποσότητας ενός LT-B παράγοντα και ενός φαρμακευτικά αποδεκτού μεταφορέα σε ένα άτομο. Συγκεκριμένα αυτή η εφεύρεση παρέχει μεθόδους για την θεραπεία του συστηματικού σοκ που επάγεται από ιό και της αναπνευστικής καταπόνησης.
CY20061100872T 1998-10-09 2006-06-26 Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα CY1105059T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (1)

Publication Number Publication Date
CY1105059T1 true CY1105059T1 (el) 2010-03-03

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100872T CY1105059T1 (el) 1998-10-09 2006-06-26 Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα

Country Status (27)

Country Link
US (3) US20020001585A1 (el)
EP (1) EP1119370B1 (el)
JP (2) JP4713738B2 (el)
KR (1) KR100888832B1 (el)
CN (1) CN1200733C (el)
AT (1) ATE329618T1 (el)
AU (1) AU777492C (el)
BR (1) BR9915025A (el)
CA (1) CA2344049C (el)
CY (1) CY1105059T1 (el)
CZ (1) CZ20011272A3 (el)
DE (1) DE69931944T2 (el)
DK (1) DK1119370T3 (el)
EA (1) EA006703B1 (el)
EE (1) EE04661B1 (el)
ES (1) ES2267294T3 (el)
HU (1) HUP0103773A3 (el)
IL (2) IL142284A0 (el)
IS (1) IS2514B (el)
NO (1) NO326905B1 (el)
NZ (1) NZ510560A (el)
PL (1) PL195264B1 (el)
PT (1) PT1119370E (el)
SG (1) SG121778A1 (el)
SK (1) SK4662001A3 (el)
TR (1) TR200100974T2 (el)
WO (1) WO2000021558A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60129010T2 (de) * 2000-04-12 2008-02-28 La Jolla Institute For Allergy And Immunology, San Diego Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
AU2004252171B2 (en) * 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2073833A2 (en) * 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2207597B1 (en) * 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
AU8228891A (en) * 1990-06-27 1992-01-23 Biogen, Inc. Surface complexed lymphotoxin
US5795964A (en) 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
WO1994013808A2 (en) 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
NZ303405A (en) 1995-01-26 2000-02-28 Biogen Inc lymphotoxin-alpha and lymphotoxin-beta heteromeric complexes to treat neoplasia
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
DE69736244T2 (de) * 1996-10-25 2007-05-31 Biogen Idec Ma Inc., Cambridge Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies

Also Published As

Publication number Publication date
CN1200733C (zh) 2005-05-11
EP1119370B1 (en) 2006-06-14
EE04661B1 (et) 2006-08-15
PL347177A1 (en) 2002-03-25
NO326905B1 (no) 2009-03-16
ES2267294T3 (es) 2007-03-01
DK1119370T3 (da) 2006-10-02
EA200100430A1 (ru) 2001-10-22
AU6296499A (en) 2000-05-01
DE69931944T2 (de) 2007-02-08
SG121778A1 (en) 2006-05-26
JP4713738B2 (ja) 2011-06-29
PT1119370E (pt) 2006-09-29
HUP0103773A3 (en) 2003-10-28
PL195264B1 (pl) 2007-08-31
SK4662001A3 (en) 2001-11-06
KR100888832B1 (ko) 2009-03-17
HUP0103773A2 (hu) 2002-01-28
JP2010155852A (ja) 2010-07-15
WO2000021558A9 (en) 2001-05-25
ATE329618T1 (de) 2006-07-15
US20040198635A1 (en) 2004-10-07
NZ510560A (en) 2003-09-26
CA2344049A1 (en) 2000-04-20
IL142284A0 (en) 2002-03-10
KR20010080073A (ko) 2001-08-22
EP1119370A1 (en) 2001-08-01
BR9915025A (pt) 2001-08-14
AU777492B2 (en) 2004-10-21
WO2000021558A1 (en) 2000-04-20
CZ20011272A3 (cs) 2001-09-12
TR200100974T2 (tr) 2001-11-21
JP2002527403A (ja) 2002-08-27
NO20011757L (no) 2001-06-08
EA006703B1 (ru) 2006-02-24
NO20011757D0 (no) 2001-04-06
US7452530B2 (en) 2008-11-18
DE69931944D1 (de) 2006-07-27
IS2514B (is) 2009-06-15
IS5882A (is) 2001-03-09
AU777492C (en) 2005-05-26
CA2344049C (en) 2009-12-15
EE200100211A (et) 2002-08-15
CN1323223A (zh) 2001-11-21
US20090087403A1 (en) 2009-04-02
IL142284A (en) 2009-11-18
US20020001585A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
CY1105059T1 (el) Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
IT1267448B1 (it) Vaccino per la prevenzione della sindrome riproduttiva e respiratoria porcina.
CY1112171T1 (el) Μτβ32α αντιγονο μυκοβακτηριδιου της φυματιωσης με απενεργοποιημενη δραστικη θεση και πρωτεϊνες συντηξης αυτου
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
DK1052905T3 (da) Kimhæmmende fremgangsmåde til rodknolde og lög med anvendelse af eugenol og/eller isoeugenol
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
MX9206408A (es) Conjugados policiclicos.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
SE0004710L (sv) System och förfarande
ES2025365B3 (es) Captador de direccion de la corriente del aire, que consta de un dispositivo electromagnetico de amortiguacion y de posicionamiento.
DE60023333D1 (de) Schaukel für behinderte
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
TR199801798T2 (xx) Otizm tedavisi.
ES2049711T3 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de cistinuria.
FI922496A0 (fi) Lineaert viskoelastisk, vattenhaltig, flytande tvaettmedelskomposition med foerbaettrad, hoeg temperatur- stabilitet, speciellt foer automatiska diskmaskiner.
NO912700D0 (no) Trekantdrager.
CO4940419A1 (es) Compuestos farmaceuticos y su utilizacion en el tratmiento de trastornos del sistema central
NO880123L (no) Selv-regulerende, ikke-last beskyttet elektronisk ballastsystem.
FI881663A0 (fi) Med luft fyllbar raeddningsflotte foer att haolla en person, som hamnat i vatten, pao ytan och slaepa honom till stranden.
TR199501282A2 (tr) Glükagon-gibi ensülinotropik peptid analoglari, bilesimleri ve kullanim yöntemleri.
MX9701031A (es) Utilizacion de la selegilina para el tratamiento de enfermedades epilepticas.
ECSP972052A (es) Quinoxalinadionas
DE29803777U1 (de) Erste Hilfe- bzw. Rettungsrückenkoffer bzw. Notfallrückenkoffer